| Literature DB >> 31339275 |
Luisa B Bay1, Inés Denzler2, Consuelo Durand3, Hernán Eiroa4, Joaquín Frabasil3, Alejandro Fainboim5, Clarisa Maxit2, Andrea Schenone3, Norma Spécola6.
Abstract
Pompe disease, also known as acid maltase deficiency or glycogenosis type II, is a rare severe, autosomal, recessive, and progressive genetic disorder caused by deficiency in alpha-glucosidase. The classic infantile-onset is the most broadly known form of Pompe disease, which presents with severe heart involvement and clear hypotonia, while the non-classic presentation occurs with early motor involvement. Late-onset Pompe disease develops in adults, but it may also occur during childhood or adolescence. Here we update the available clinical and diagnostic findings because an early management with enzyme replacement therapy may improve patients' survival and quality of life. We also review the benefits and adverse effects of available treatments and new lines of therapeutic research. Sociedad Argentina de Pediatría.Entities:
Keywords: Cardiomyopathies; Glycogenosis type II; Motor disorders; Muscular hypotonia; Pompe disease
Year: 2019 PMID: 31339275 DOI: 10.5546/aap.2019.eng.271
Source DB: PubMed Journal: Arch Argent Pediatr ISSN: 0325-0075 Impact factor: 0.635